Expected Moves

Actual outcome: Mixed · $2.33 at outcome

Nkarta reported Q2 2026 EPS of -$0.37, exactly in line with consensus estimates. The company's updates regarding its cash runway and registrational trial enrollment provided no significant surprises to alter investor sentiment. Consequently, the stock remained flat as the market digested the anticipated progress without a clear directional catalyst.

Actual outcome: Bear · $2.65 at outcome

NKTX executed a dilutive secondary equity offering to shore up its exhausted balance sheet. The market reacted negatively to the resulting shareholder dilution and ongoing cash burn concerns, driving the stock down 10.8% by the outcome date and eventually pushing it below the bear floor.

Actual outcome: Bull · $2.68 at outcome

Nkarta reported its first-quarter 2026 results, highlighting ongoing enrollment at the 4 billion cell dose level for its Ntrust-1 and Ntrust-2 autoimmune trials alongside a new regulatory agreement supporting outpatient dosing in community-based settings. The stock reacted positively because the shift to outpatient dosing significantly reduces patient burden, expanding the therapy's potential accessibility and commercial viability. Furthermore, the confirmation that initial clinical data from both trials will be presented at a medical meeting later in the year provided investors with a clear, near-term catalyst.

Actual outcome: Bear · $2.64 at outcome

Nkarta reported Q1 2026 EPS of -$0.37, which was exactly in-line with consensus estimates. However, the corporate update lacked immediate clinical catalysts, noting only ongoing enrollment for its Ntrust trials and pushing expectations for initial data to a future medical meeting later in 2026. This absence of near-term upside drivers disappointed investors, causing the stock to drop 19.5% and break below the bear floor shortly after the release.

Actual outcome: Mixed · $2.19 at outcome

Nkarta reported in-line Q4 2025 EPS of -$0.37 and announced a strategic workforce reorganization to add autoimmune clinical expertise. The company also revealed plans to escalate doses of its CAR-NK therapy NKX019 to a 12 billion cell regimen aimed at deepening B-cell depletion, which encouraged investors and ultimately drove the stock well past the bull target in the following weeks.